Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 56

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 56
---
 debt, obtain financing necessary to operate our business, recruit and retain qualified
personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions
and collaborative arrangements we may pursue; the ongoing communications with the U.S. Food and Drug Administration relating to compliance
and quality plans at our outsourcing facility in New Jersey; competition from pharmaceutical companies, outsourcing facilities and pharmacies;
general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties
related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance
of our current and any future formulations and compounding pharmacies generally; and the other risks and uncertainties described under
the heading “Risk Factors” in Part II, Item 1A of this Quarterly Report and in our other filings with the SEC. You should
not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made and, except
as required by law, we undertake no obligation to revise or publicly update any forward-looking statement for any reason.

Overview

We
are a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that
address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration,
cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a
commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. 

31

Factors
Affecting Our Performance

We
believe the primary factors affecting our performance are our ability to increase revenues of our branded pharmaceutical products, proprietary
compounded formulations and certain non-proprietary products, grow and gain operating efficiencies in our operations, avoid or mitigate
any potential regulatory-related restrictions, optimize pricing and obtain reimbursement options for our drug products, and continue
to pursue development and commercialization opportunities for certain of our ophthalmology and other assets that we have not yet made
commercially available. We believe we have built a tangible and intangible infrastructure that will allow us to scale revenues efficiently
in the near and long-term. All of these activities may require significant costs and other resources, which we may not have or be able
to obtain from operations or other sources. See “Liquidity and Capital Resources” below.

Recent
Develop